Trials / Completed
CompletedNCT01720095
Niapsan as Add -on Therapy to Antipsychotic Treatment in First Episode Psychosis
A 1 Year Randomized, Controlled, Open-Label Study of the Impact of Flexible Doses of Niacin (NIASPAN) as an Adjunct to Antipsychotic Medication in the Treatment of First Episode Psychosis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Nova Scotia Health Authority · Academic / Other
- Sex
- All
- Age
- 18 Years – 35 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to help understand if by adding Niaspan FCT (study drug) to antipsychotic medications will it help maintain or improve cognitve functioning.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Niaspan |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
- First posted
- 2012-11-02
- Last updated
- 2015-08-07
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01720095. Inclusion in this directory is not an endorsement.